257 results
ARS
2023 FY
MYGN
Myriad Genetics, Inc.
17 Apr 24
Annual report to shareholders
4:33pm
for PARP inhibitor therapy. HRD status is determined using two independent methods: BRCA1 and BRCA2 status that encompasses sequence variants and large … , or, if none apply, an amount determined by an independent dispute resolution entity. The cost-sharing amount is limited to an amount determined
8-K
EX-99.1
rjhrrfvv zta
16 Jan 24
Results of Operations and Financial Condition
9:00am
8-K
EX-1.1
7dow5a 0ax1
13 Nov 23
Entry into a Material Definitive Agreement
4:31pm
424B5
2qx vjrk493
13 Nov 23
Prospectus supplement for primary offering
6:02am
424B5
jk5flvq8i6227r1jf19b
8 Nov 23
Prospectus supplement for primary offering
4:05pm
S-3ASR
EX-4.3
8uk3v7
8 Nov 23
Automatic shelf registration
4:01pm
S-3ASR
EX-23.1
x8pgxpugq89oln
8 Nov 23
Automatic shelf registration
4:01pm
S-3ASR
13lds2bj
8 Nov 23
Automatic shelf registration
4:01pm
8-K
EX-10.1
f39ivmzd
5 Oct 23
Departure of Directors or Certain Officers
8:30am
8-K
EX-99.1
6c64 f8g7gut8b
3 Aug 23
Results of Operations and Financial Condition
4:05pm
8-K
EX-10.1
jgl9bj51u21c5g
6 Jul 23
Entry into a Material Definitive Agreement
8:24am
8-K
EX-10.2
z3rbyjrf
6 Jul 23
Entry into a Material Definitive Agreement
8:24am
8-K
m9uznz gq5kxk3
2 Jun 23
Departure of Directors or Certain Officers
4:31pm